全文获取类型
收费全文 | 286篇 |
免费 | 13篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 1篇 |
基础医学 | 36篇 |
口腔科学 | 3篇 |
临床医学 | 8篇 |
内科学 | 100篇 |
皮肤病学 | 61篇 |
神经病学 | 9篇 |
特种医学 | 11篇 |
外科学 | 18篇 |
预防医学 | 17篇 |
眼科学 | 3篇 |
药学 | 11篇 |
肿瘤学 | 20篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 12篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 12篇 |
2013年 | 6篇 |
2012年 | 17篇 |
2011年 | 22篇 |
2010年 | 8篇 |
2009年 | 7篇 |
2008年 | 17篇 |
2007年 | 17篇 |
2006年 | 21篇 |
2005年 | 16篇 |
2004年 | 14篇 |
2003年 | 15篇 |
2002年 | 11篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1998年 | 5篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 2篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 1篇 |
排序方式: 共有303条查询结果,搜索用时 15 毫秒
1.
2.
Masayuki Amagai Yoshio Inokuchi Takeji Nishikawa Yoshiko Shimizu Nobuyoshi Shimizu 《Somatic Cell and Molecular Genetics》1989,15(2):153-158
The tumor promoter 12-O -tetradecanoylphorbol-13-acetate (TPA) induces DNA synthesis in quiescent 3T3-L1 cells but not in its variant VT-1 cells. A gt10 cDNA library was constructed using poly(A)+ RNA from 3T3-L1 cells that were stimulated by TPA for 20 min. Radioactive cDNA probes were prepared from mRNAs of TPA-treated 3 T3-L1 and VT-1 cells and used for screening of the 3T3-L1 cDNA library by differential hybridization. Nine of 6000 phage plaques hybridized only to the 3T3-L1 cDNA probe. Analysis of the nucleotide sequence of five of these clones indicated a high degree of homology with human or mouse type I and type III collagen genes. Three other independent clones showed no homology with any known DNA sequences. These isolated clones of TPA-inducible early (TIE) genes may be useful to study the signal transduction pathway of phorbol esters. 相似文献
3.
Tomoo Yamazaki Satoru Joshita Eriko Kasuga Kazuki Horiuchi Ayumi Sugiura Naoyuki Fujimori Michiharu Komatsu Takeji Umemura Akihiro Matsumoto Eiji Tanaka 《Journal of infection and chemotherapy》2018,24(5):393-397
A 73-year-old woman was admitted with consciousness disturbance following a fever. Abdominal computed tomography revealed a large liver abscess with which the presence of Desulfovibrio desulfuricans and Escherichia coli was confirmed by thorough blood and abscess content culture. Empiric meropenem treatment was switched to cefoperazone/sulbactam, followed by ampicillin/sulbactam based on susceptibility testing. Desulfovibrio desulfuricans is a common bacterium that rarely causes liver abscess and may be overlooked during co-infection due to overgrowth of the accompanying bacteria. Clinicians should bear Desulfovibrio desulfuricans in mind and select the appropriate antibiotics according to susceptibility testing when anaerobic bacteria are detected in a liver abscess. 相似文献
4.
Sakamoto Kazumasa Ito Kiyoaki Yotsuyanagi Hiroshi Yatsuhashi Hiroshi Tanaka Yasuhito Hige Shuhei Takikawa Yasuhiro Ueno Yoshiyuki Yamamoto Kazuhide Imazeki Fumio Inoue Jun Kurosaki Masayuki Umemura Takeji Toyoda Hidenori Mita Eiji Michitaka Kojiro Maeshiro Tatsuji Yamada Norie Suetsugu Atsushi Kawanaka Miwa Seko Yuya Matsuura Kentaro Okumura Akinori Fukuzawa Yoshitaka Sugiyama Masaya Mizokami Masashi Yoneda Masashi 《Journal of gastroenterology》2022,57(12):971-980
Journal of Gastroenterology - Hepatitis B virus (HBV) is one of the most prevalent chronic viral infections that causes chronic hepatitis B (CHB). In Japan, genotypes B and C account for most of... 相似文献
5.
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis 总被引:9,自引:0,他引:9
Sato S Hirakata M Kuwana M Suwa A Inada S Mimori T Nishikawa T Oddis CV Ikeda Y 《Arthritis and rheumatism》2005,52(5):1571-1576
OBJECTIVE: To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C-ADM). METHODS: Autoantibodies were analyzed by immunoprecipitation in 298 serum samples from patients with various connective tissue diseases (CTDs) or idiopathic pulmonary fibrosis (IPF). Antigen specificity of the sera was further examined by immunoblotting and indirect immunofluorescence (IF). The disease specificity and clinical features associated with the antibody of interest were determined. RESULTS: Eight sera recognized a polypeptide of approximately 140 kd (CADM-140 autoantigen) by immunoprecipitation and immunoblotting. Immunoreactivity was detected in the cytoplasm, and indirect IF revealed a granular or reticular pattern. Anti-CADM-140 antibodies were detected in 8 of 42 patients with DM, but not in patients with other CTDs or IPF. Interestingly, all 8 patients with anti-CADM-140 antibodies had C-ADM. Among 42 patients with DM, those with anti-CADM-140 autoantibodies had significantly more rapidly progressive interstitial lung disease (ILD) when compared with patients without anti-CADM-140 autoantibodies (50% versus 6%; P = 0.008). CONCLUSION: These results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM. Further attention should be directed to the detection of rapidly progressive ILD in those patients with anti-CADM-140 autoantibodies. 相似文献
6.
7.
Masao Omata Shuhei Nishiguchi Yoshiyuki Ueno Hitoshi Mochizuki Namiki Izumi Fusao Ikeda Hidenori Toyoda Osamu Yokosuka Kazushige Nirei Takuya Genda Takeji Umemura Tetsuo Takehara Naoya Sakamoto Yoichi Nishigaki Kunio Nakane Nobuo Toda Tatsuya Ide Mikio Yanase Keisuke Hino Bing Gao Kimberly L. Garrison Hadas Dvory‐Sobol Akinobu Ishizaki Masa Omote Diana Brainard Steven Knox William T. Symonds John G. McHutchison Hiroshi Yatsuhashi Masashi Mizokami 《Journal of viral hepatitis》2014,21(11):762-768
Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV – peginterferon and ribavirin for 24 weeks – is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a phase 3, open‐label study to assess the efficacy and safety of an all‐oral combination of the NS5B polymerase inhibitor sofosbuvir and ribavirin in patients with chronic genotype 2 HCV infection in Japan. We enrolled 90 treatment‐naïve and 63 previously treated patients at 20 sites in Japan. All patients received sofosbuvir 400 mg plus ribavirin (weight‐based dosing) for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after therapy (SVR12). Of the 153 patients enrolled and treated, 60% had HCV genotype 2a, 11% had cirrhosis, and 22% were over the aged 65 or older. Overall, 148 patients (97%) achieved SVR12. Of the 90 treatment‐naïve patients, 88 (98%) achieved SVR12, and of the 63 previously treated patients, 60 (95%) achieved SVR12. The rate of SVR12 was 94% in patients with cirrhosis and in those aged 65 and older. No patients discontinued study treatment due to adverse events. The most common adverse events were nasopharyngitis, anaemia and headache. Twelve weeks of sofosbuvir and ribavirin resulted in high rates of SVR12 in treatment‐naïve and previously treated patients with chronic genotype 2 HCV infection. The treatment was safe and well tolerated by patients, including the elderly and those with cirrhosis. 相似文献
8.
Yasuhiro Miyake Kazuhide Yamamoto Hiroshi Matsushita Masanori Abe Atsushi Takahashi Takeji Umemura Atsushi Tanaka Makoto Nakamuta Yasunari Nakamoto Yoshiyuki Ueno Toshiji Saibara Hajime Takikawa Kaname Yoshizawa Hiromasa Ohira Mikio Zeniya Morikazu Onji Hirohito Tsubouchi Intractable Hepato‐Biliary Disease Study Group of Japan 《Hepatology research》2014,44(13):1299-1307
9.
10.
Matsumoto A Tanaka E Morita S Yoshizawa K Umemura T Joshita S 《Journal of gastroenterology》2012,47(9):1006-1013